Canadian Association of Radiation Oncology Annual Scientific Meeting (CARO ASM)  
September 28-October 1, 2022

Optimizing Patient Outcomes: The Intersection of Technology and Human Touch  
Program Objectives: At the end of the conference, the participants will be able to:
- demonstrate an understanding of innovative radiotherapy techniques and current evidence for use in clinical practice;
- discuss how patient- and tumour-specific factors play a role in recommended new technologies and treatment modalities;
- describe the factors that lead to inequities in cancer care delivery;
- describe the implications of implementing newer radiotherapy techniques within a center, including opportunities for education, research, and clinical practice.

PROGRAM - Last update: April 27, 2022

Wednesday September 28, 2022

8:00-4:00  
**Resident Refresher Course** - Toronto Ballroom (TB) I  
Facilitator: Sarah Hamilton

Objectives: By the end of this session, the participants will be able to:
- review the principles of management and the role of radiotherapy in sarcoma, endometrial cancer, and high risk prostate cancer;
- explore the evidence and indications for neoadjuvant radiotherapy for rectal cancer;
- develop a radiotherapy treatment plan evaluation approach.

8:00-9:00  
Registration – Convention Level

9:00-9:10  
Welcome and Introductions

9:10-10:40  
Treatment Planning Evaluation  
Jennifer Croke, Jeff Winter

10:40-11:00  
Refreshment Break

11:00-11:30  
The Role of Radiotherapy in Sarcoma  
Philip Wong

11:30-11:45  
Discussion Period
11:45-1:15
Lunch
1:15-1:45

1:15-1:45
The Role of Neoadjuvant Rectal Cancer
Will Chu

1:45-2:00
Discussion Period

2:00-2:30
Endometrial Cancer
Tbd

2:30-2:45
Discussion Period

2:45-3:05
Refreshment Break

3:05-3:35
High Risk/Locally Advanced Prostate Cancer
Peter Chung

3:35-3:50
Discussion Period

3:50-4:00
Closing Remarks
Sarah Hamilton

5:00-6:00
Resident Career Counselling Social - 2nd floor Bridge Foyer

6:00-9:00
CARO Board Meeting
Governor General, 2nd floor
Thursday September 29, 2022 - Convention Level

7:00-8:00
Registration and Breakfast
Exhibit Hall

8:00-8:15
Welcome and Introductions - TB I/II/III
Jennifer Croke
Jolie Ringash

8:15-9:45
Theme Symposium - TB I/II/III
Title:
Moderators: David Roberge, Teri Stuckless

Objectives: By the end of this symposium, the participants will be able to:
- Demonstrate an understanding of the factors shaping the experience of individuals diagnosed with cancer as they navigate radiation treatment.
- Recognize the technical, fiscal, and human resource considerations associated with the clinical implementation of novel treatment technologies and techniques.
- Identify evaluative approaches and research opportunities to assess the impact of new treatment technologies and techniques on patient outcomes.
- Illustrate novel methods for educating current and future radiation health professionals.

9:45-10:30
Refreshment Break
Exhibit Hall

10:30-11:15
CARO Lecture - TB I/II/III
Moderator: Jolie Ringash

Title:
Speaker: Sue Yom

Objectives: By the end of this session, the participants will be able to:
Xx
xx

11:15-11:30
Question & Answer Period
Objective: By the end of this session, the participants will be able to:

1. A RANDOMIZED PHASE III TRIAL COMPARING HEALTH-RELATED QUALITY OF LIFE AFTER LOW DOSE RATE (LDR) OR HIGH DOSE RATE (HDR) PROSTATE BRACHYTHERAPY BOOST COMBINED WITH EXTERNAL BEAM PELVIC RADIOThERAPY (EBRT)
   Nikitha Moideen

2. IMPACT OF MGMT PROMOTER METHYLATION STATUS ON TUMOR DYNAMICS DURING WEEKLY ADAPTIVE RADIOThERAPY FOR GLIOBLASTOMA
   John M. Hudson

3. ASSESSING TREATMENT RESPONSE AFTER LUNG SABR: AN EVALUATION OF THE PREDICTIVE VALUE OF RECIST CRITERIA
   Stephanie Gulstene

4. A PHASE II TRIAL OF CONCURRENT SUNITINIB, TEMOZOLOMIDE AND RADIATION THERAPY FOLLOWED BY ADJUVANT TEMOZOLOMIDE FOR NEWLY DIAGNOSED GLIOBLASTOMA PATIENTS WITH AN UNMETHYLATED MGMT GENE PROMOTER (A01-M121-11A, MCG1132)
   Mame Daro Faye

5. LONG TERM TOXICITIES OF ADOLESCENT AND YOUNG ADULT SURVIVORS OF CERVIX CANCER WHO UNDERWENT RADIATION THERAPY: A CROSS-SECTIONAL ANALYSIS
   Andrew Pritchard

6. SAFETY AND EFFICACY OF STEREOTACTIC BODY RADIOTHERAPY FOR ULTRA-CENTRAL THORACIC TUMOURS
   George J. Li

12:30-2:30
Lunch
Industry Symposium - Governor General, 2nd fl
Visit Exhibit Hall
Committee Meetings - tbd

12:45-1:45
Women in Radiation Medicine - Carmichael Jackson

Title:
Mira Keyes

Objective: By the end of this session, the participants will be able to:

Xx
XX
2:30-3:30
**Oral Session 1 – Population Science** - TB I
Moderators:

Objectives: By the end of this session, the participants will be able to:

1. **RATES OF REGIONAL RADIOTHERAPY RECEIPT OVER TIME IN LOW-RISK, NODE POSITIVE BREAST CANCER**
   Daegan Sit
2. **First Pan-Canadian Consensus Recommendations for Proton Beam Therapy Access in Canada**
   Gunita Mitera
3. **TRENDS IN RADIOTHERAPY FRACTIONATION IN ONTARIO FROM 2011/12 TO 2020/21 FOR THE MAJOR DISEASE SITES AND THE IMPACT OF COVID19**
   Jonathan Wang
4. **COST MINIMIZATION ANALYSIS OF CONVENTIONAL VERSUS SHORT-COURSE RADIOTHERAPY WITH TEMOZOLOMIDE FOR NON-ELDERLY PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA**
   Jordan Hill
5. **Health-economics and evidence-based hypofractionation: A European cluster analysis with relevance to North America**
   Carol Oliveira
6. **TUMOUR AND PATIENT FACTORS INFLUENCING THE USE OF ADJUVANT RADIOTHERAPY IN LOCALLY ADVANCED HEAD AND NECK CANCER**
   Matthew Beckett

2:30-3:30
**Oral Session 2 – Applied Physics and Technology** - TB II/III
Moderators:

Objectives: By the end of this session, the participants will be able to:

7. **Photon vs. Proton Whole Ventricular Radiotherapy for Intracranial Non-Germinomatous Germ Cell Tumors - A Report from the Children’s Oncology Group**
   Zain Siddiqui
8. **KNOWLEDGE-BASED PLANNING TO IMPROVE AND AUTOMATE PATIENT-SPECIFIC QUALITY ASSURANCE PROCEDURES IN CLINICAL TRIALS - UPDATED SECONDARY ANALYSIS OF CCTG HN6**
   Srinivas Raman
9. **A COMPARISON OF THREE DIFFERENT BREATH HOLD TECHNIQUES USED FOR REDUCING CARDIAC DOSE FOR PATIENTS RECEIVING LEFT-SIDED BREAST CANCER RADIATION THERAPY**
   Anh Hoang
RADCURE: A LARGE OPEN SOURCE HEAD AND NECK RADIATION THERAPY DATASET FOR DATA SCIENCE
Andrew Hope

INITIAL ASSESSMENT OF A COMMERCIAL AUTO-SEGMENTATION SOFTWARE BASED ON DEEP-LEARNING MODELS IN THE CONTEXT OF ARTIFICIAL INTELLIGENCE-ASSISTED RADIATION TREATMENT PLANNING
MING PAN

A RANDOMISED BLINDED ASSESSMENT OF A MACHINE LEARNING BASED AUTOCONTOURING TOOL FOR BREAST CANCER RADIOTHERAPY COMPARED TO PEER-REVIEWED RADIATION ONCOLOGIST CONTOURS
Michael Kucharczyk

3:30-4:30
Poster Discussion 1- TB I
Moderators:

Objectives: By the end of this session, the participants will be able to:

Xx
Xx

ELIMINATING TATTOOS FOR SHORT COURSE PALLIATIVE RADIOTHERAPY: SET-UP ERROR, SATISFACTION AND COST
Joanna Javor

Does a subspecialty gynecologic pathology review change management of endometrial cancer patients: A BC Cancer- Victoria experience
Jennifer Rauw

The non-operative management using SBRT for technically resectable, but medically inoperable, pancreatic adenocarcinoma
Benjamin Royal-Preyra

ACUTE TOXICITY IN HIGH-RISK PROSTATE CANCER PATIENTS TREATED WITH EXTREME HYPOFRACTIONATION (HRPC-SBRT)
Sergio Faria

DOSE TO THE INTERNAL MAMMARY CHAIN LYMPH NODES IN CASES WITH INTERNAL MAMMARY LYMPH NODE RELAPSE: A CASE CONTROL STUDY
Louise Wade

POPULATION-BASED OUTCOMES OF GYNECOLOGIC CANCER PATIENTS TREATED WITH WHOLE BRAIN OR STEREOTACTIC RADIOTHERAPY FOR BRAIN METASTASES
Timothy Kong

PREDICTORS OF EARLY POLYMETASTATIC RELAPSE FOLLOWING STEREOTACTIC ABLATIVE RADIOTHERAPY FOR UP TO 5 OLIGOMETASTASES: A SECONDARY ANALYSIS OF THE PHASE II SABR-5 TRIAL
Sarah Baker

DO ANTHROPOMETRIC INDICES CORRELATE WITH PROSTATE CANCER IN NIGERIAN MEN?
Kehinde Adeyinka
ENSURING SUPERIOR REPORTING OF NON-INFERIORITY RADIOTHERAPY CLINICAL TRIALS: A SYSTEMATIC REVIEW  
Andrew Arifin

RADIATION DOSE, TECHNIQUE, AND USE OF BRAIN RADIATION ON OVERALL SURVIVAL IN PATIENTS WITH LIMITED-STAGE SMALL CELL LUNG CANCER  
Shelly Palchik

3:30-4:30  
**Poster Discussion 2 - TB II/III**  
Moderators:

Objectives: By the end of this session, the participants will be able to:

Xx

Xx

MULTI-TARGET THORACIC STEREOTACTIC BODY RADIOTHERAPY - TOXICITY AND EFFICACY ANALYSIS  
Eric Nguyen

PERSON-CENTERED RADIATION THERAPY FOR BREAST CANCER PATIENTS: PATIENT EXPERIENCES FROM A PROSPECTIVE RANDOMIZED TRIAL (PERSON)  
Vivian Hoang

INCIDENCE AND MANAGEMENT TRENDS IN LOCALLY ADVANCED HEAD AND NECK NON-MELANOMA SKIN CANCER  
Ka-Kit David Yeung

Pain and Interventions in Stage IV Non-Small Cell Lung Cancer: A Province-Wide Analysis  
Vivian Tan

ERECTILE FUNCTION AFTER 60GY IN 20 FRACTIONS EXTERNAL BEAM RADIOTHERAPY TO THE PROSTATE  
Conrad Bayley

NEUROMODULATORY EFFECT AND DOSE RESPONSE OF FUNCTIONAL RADIOSURGERY ON CORTICAL NEURONS  
Megan Boucher-Routhier

STEREOTACTIC BODY RADIOTHERAPY FOR RENAL CELL CARCINOMA: ONCOLOGIC AND RENAL FUNCTION OUTCOMES  
Rachel Glicksman

EVALUATION OF USE OF ADJUVANT RADIOTHERAPY AND SURGICAL APPROACH WITH RESPECT TO ONCOLOGIC OUTCOMES IN THE MANAGEMENT OF EARLY-STAGE CERVICAL CARCINOMA  
Laura Burgess

OUTCOMES OF 30GY IN 4 FRACTIONS FOR SPINE STEREOTACTIC BODY RADIOTHERAPY  
Daniel Palhares

A BRITISH COLUMBIA BASED POPULATION STUDY ON THE TREATMENT AND LONG-TERM OUTCOMES OF THYMOMA: A 25-YEAR RETROSPECTIVE REVIEW  
Eric Wu

4:30-6:00  
**Mentorship Session - Governor General, 2nd fl**
7:00
**Welcome Reception**
Backyard Party at The Ballroom
145 John Street
[www.theballroom.ca](http://www.theballroom.ca)

**Friday September 30, 2022 - Convention Level**

7:00-8:00
*Breakfast Symposium – Governor General*
Exhibit Hall

7:00-8:00
*Registration and Breakfast - Convention Level*
Committee Meetings - tbd

8:00-9:00
**Oral Session 3 – Education and Survivorship TB 1**
Moderators:

Objectives: By the end of this session, the participants will be able to:
Xx
Xx

19  **EVALUATION OF SIMULATION-BASED VIRTUAL PATIENT ENCOUNTERS FOR LEARNING ONCOLOGIC EMERGENCY MANAGEMENT**
Vanessa Di Lalla

20  **OPTIMIZING PATIENT-CENTERED INCLUSIVE CARE IN ONCOLOGY: HEALTHCARE PROFESSIONALS’ KNOWLEDGE, ATTITUDES AND PRACTICES CARING FOR LGBQT2+ INDIVIDUALS**
Nazlin Jivraj

21  **DOES A MENTORSHIP AWARD IN RADIATION ONCOLOGY INSPIRE MEDICAL STUDENTS TO PURSUE THE SPECIALTY? A SURVEY ANALYSIS OF MEDICAL STUDENTS, RESIDENT MENTORS, AND RESEARCH PROJECT SUPERVISORS**
Ruijia Jin

22  **VALIDATION OF THE BC-BRAIN PATIENT REPORTED OUTCOME QUESTIONNAIRE FOR PATIENTS WITH CENTRAL NERVOUS SYSTEM TUMOURS TREATED WITH RADIOTHERAPY**
Ling Yan

23  **LONG TERM RESULTS OF A LONGITUDINAL STUDY OF UNMET SURVIVORSHIP NEEDS IN PATIENTS WITH HEAD AND NECK CANCER**
Ionut Busca

24  **EQUITY AS AN EMERGING FOCUS IN THE CANADIAN CANCER CARE SECTOR: RESULTS OF A RAPID SCOPING REVIEW**
Michael McKenzie
8:00-9:00
**Oral Session 4 – Breast and GI Cancer - TB II/III**

Moderators:

Objectives: By the end of this session, the participants will be able to:

Xx
Xx

25 ONCOLOGIC OUTCOME, TOXICITY AND COSMESIS AFTER SINGLE-FRACTION NEOADJUVANT RADIOTHERAPY FOR LOW-RISK BREAST CANCER
Danny Lavigne

26 ADJUVANT RADIOTHERAPY (RT) FOR BREAST CANCER PATIENTS WITH REMOTE RECONSTRUCTION: INSTITUTIONAL OUTCOMES
Nina Samson

27 EARLY INSTITUTIONAL EXPERIENCE OF ULTRA-HYPOFRACTIONATED BREAST RADIOTHERAPY IN A LARGE ACADEMIC CANCER CENTRE
Hiba Othman

28 DOSIMETRIC PARAMETERS CORRELATED WITH TOXICITY WITH SHORT COURSE RADIATION IN THE NEOADJUVANT TREATMENT OF RECTAL CANCERS
Yugmel Nijjar

29 AN EXAMINATION OF RECTAL ANATOMY DEFINITIONS AND FUTURE DIRECTIONS
Yiming (Michael) Zhu

30 STATIN THERAPY IN PATIENTS UNDERGOING SHORT-COURSE NEOADJUVANT RADIOTHERAPY FOR RECTAL CANCER
Daniel Schep

9:00-10:00
**Oral Session 5 – Stereotactic Radiosurgery - TB I**

Moderators:

Objectives: By the end of this session, the participants will be able to:

Xx
Xx

31 SINGLE FRACTION PERIPHERAL LUNG SBRT DURING THE GLOBAL COVID-19 PANDEMIC AT A CANCERCARE MANITOBA: AN ANALYSIS OF TECHNICAL FEASIBILITY AND CLINICAL SAFETY
Salem Alfaifi

32 SETUP AND TREATMENT EFFICIENCY OF 2 PROSTATE SBRT RECTAL PREPARATION TECHNIQUES: EXPERIENCE FROM PROGRAM DEVELOPMENT AT A COMMUNITY CENTRE
Amanda Lamb

33 A PROSPECTIVE RANDOMIZED PARALLEL-CONTROLLED PILOT TRIAL OF STEREOTACTIC BODY RADIATION THERAPY VS. RADIOFREQUENCY ABLATION FOR THE MANAGEMENT OF SMALL RENAL MASSES - INITIAL RESULTS
Anand Swaminath
34 OUTCOMES OF STEREOTACTIC BODY RADIOTHERAPY FOR METASTASES TO THE HEAD AND NECK
Irene Karam

35 Immunotherapy and the risk of radiation necrosis in brain metastases patients treated with stereotactic radiosurgery
Benjamin Royal-Preyra

36 PROGRESSION-FREE SURVIVAL AND LOCAL CONTROL FOLLOWING STEREOTACTIC ABLATIVE RADIOTHERAPY FOR UP TO 5 OLIGOMETASTASES: AN ANALYSIS FROM THE POPULATION-BASED PHASE II SABR-5 TRIAL
Sarah Baker

9:00-10:00
Oral Session 6 – Variety Pack - TB II/III
Moderators:

Objectives: By the end of this session, the participants will be able to:
Xx
Xx

37 CLINICAL OUTCOMES OF MEDULLOBLASTOMA PATIENTS TREATED WITH PROTON RADIOTHERAPY: A SYSTEMATIC REVIEW
Sympascho Young

38 MALIGNANT SALIVARY GLAND TUMORS AND LONGTERM PATIENTS OUTCOMES BASED ON THE AMERICAN JOINT COMMITTEE ON CANCER 8TH EDITION STAGING SYSTEM
Daegan Sit

39 A NOVEL, RAPID AND SIMPLE (RAPPLE) PARTIAL BRAIN RADIOTHERAPY TECHNIQUE TO TREAT BRAIN METASTASIS: A RETROSPECTIVE REVIEW OF OUTCOMES
Timothy Kong

40 EVALUATING MULTIDISCIPLINARY PEER REVIEW: A RETROSPECTIVE STUDY OF PLAN MODIFICATIONS IN RADICAL AND PALLIATIVE INTENT RADIATION THERAPY TREATMENTS
Adrian Cozma

41 Outcomes of Extracranial Oligorecurrence after Prior Metastases Directed Stereotactic Body Radiotherapy for Oligometastatic Disease
Jonathan Peng

42 A COMPETING RISK ANALYSIS OF PROGNOSTIC FACTORS FOR LOCAL AND REGIONAL RECURRENCE AND SURVIVAL OUTCOMES IN EARLY-STAGE NON-SMALL CELL LUNG CANCER TREATED WITH STEREOTACTIC ABLATIVE RADIATION THERAPY
Marion Tonneau

10:00-11:00
Refreshment Break
Poster Viewing – TB III, TB III Aisle, Johnston, Tom Thomson
Exhibit Hall
11:00-12:00
Fellow Competition - TB I/II/III
Moderators:

Objectives: By the end of this session, the participants will be able to:
Xx
Xx

43 PREDICTIVE FACTORS FOR SURVIVAL AND RADIATION NECROSIS IN PATIENTS WITH RECURRENT HIGH-GRADE GLIOMA TREATED WITH RE-IRRADIATION
Daniel Palhares

44 Long-term Outcomes of SABR to Primary Renal Cell Carcinoma: A Multi-Centre Analysis from The International Radiosurgery Oncology Consortium for Kidney (IROCK)
Rohann Correa

45 TREATMENT PATTERNS AND OUTCOMES OF PATIENTS WITH HIGH-GRADE GLIOMA DURING THE COVID-19 PANDEMIC
Ghufran Aljawi

46 PSMA-PET/CT guided intensification of radiotherapy for prostate cancer (PSMAgRT): findings of detection rate, impact on cancer management, and early toxicity from a phase 2 randomised controlled trial
Claire Petit

47 MATURE LOCAL CONTROL AND REIRRADIATION RATES COMPARING SPINE STEREOTACTIC BODY RADIOTHERAPY TO CONVENTIONAL PALLIATIVE EXTERNAL BEAM RADIOTHERAPY
K. Liang Zeng

48 STEREOTACTIC BODY RADIATION THERAPY FOR NON-SPINE BONE METASTASES: LOCAL CONTROL AND FRACTURE RISK
Eric Nguyen

12:00-1:50
Lunch
Symposium – Governor General
Visit Exhibit Hall
Committee Meetings - tbd
Yoga 12:15-12:45 – poolside or walkway

1:50-2:00
Truth and Reconciliation Tribute - TB I/II/III
2:00-2:45  
**CARO Gold Medal and Gordon Richards Lecture** - TB I/II/III  
Moderator:  
Introduction:  

Title:  
David Palma  

Objectives: By the end of this session, the participants will be able to:  
Xx  
xx  

2:45-3:00  
Question & Answer Period  

3:00-4:15  
**Workshop 1** - Jackson  
Pan-Canadian Expansion of Electronic Patient Reported Outcomes (ePROs): A Patient Engagement Tool Needed More than Ever  
Amanda Caissie  

Objectives: By the end of this session, the participants will be able to:  
- Illustrate the current state of the pan-Canadian PRO radiotherapy (recently divested from CPQR to CARO), using examples from PROs initiatives in Canadian radiotherapy centres;  
- Identify the clinical benefits of PROs from point of care clinical use (symptom monitoring/management) to patient triage models: real-life examples from early PRO adopters;  
- To guide future PRO program expansion, apply lessons learned from early adopters in PROs implementation: from change management strategies to navigation of IT challenges and PROs use for quality improvement.  

3:00-4:15  
**Workshop 2** - Carmichael  
Integrating Equity-oriented Healthcare Into Cancer Care Practice  
Michael McKenzie  

Objectives: By the end of this session, the participants will be able to:  
- Discuss health and healthcare equity, and how inequities impact patient experiences and outcomes in the cancer care sector;  
- Begin applying an equity lens in clinical settings and practice;  
- Explore strategies and existing tools for integrating equity-oriented approaches at a systems level.
3:00-4:15
**Workshop 3 - Governor General**
Future of SABR Trials in Oligometastatic Cancer
Robert Olson

Objectives: By the end of this session, the participants will be able to:
- Review current state of SABR clinical trials;
- Review candidate future clinical trials;
- Select Canadian led SABR trials to further develop.

4:15-4:30
Refreshment/Stretch Break

4:30-6:00
**Annual General Meeting** (By Invitation Only) - TB II/III

7:00
**Dinner and Awards Ceremony** - TB I/II

**Saturday October 1, 2022 - Convention Level**

7:00-8:00
Breakfast Symposium - Governor General
Committee Meetings - tbd

7:00-8:00
**CROF Fun Run/Walk**
Meet in the lobby of the hotel at University Avenue Doors

8:00-8:45
**Jean Roy Lecture** - TB I
Moderator:
Introduction:

Title:
Mark Corkum

Objectives: By the end of this session, the participants will be able to:
- X
- X

8:45-9:00
Question & Answer Period
9:00-10:00  
**Canadian Brachytherapy Group Oral Session - TB I**  
Moderators:

Objectives: By the end of this session, the participants will be able to:
Xx  
xx

49  AUTOMATED CATHETER TRACKING IN 3D ULTRASOUND IMAGES FROM HIGH-DOSE-RATE PROSTATE BRACHYTHERAPY USING DEEP LEARNING AND FEATURE EXTRACTION  
Nicole Kitner

50  A PILOT STUDY OF SALVAGE HDR BRACHYTHERAPY IN RECURRENT PROSTATE CANCER: 5 YEAR TOXICITY AND OUTCOMES  
Maxence Cloutier

51  PATIENT’S REPORTED OUTCOMES (PROs) OF AN ULTRA-HYPO FRACTIONATED (UHF) PROSTATE IMAGE GUIDED RADIATION THERAPY (IGRT) WITH HDR BRACHYTHERAPY BOOST (BB) AS COMPARED TO A MODERATE HYPO FRACTIONATED (MHF) APPROACH: INTERIM ANALYSIS OF A PHASE TWO STUDY  
Andre-Guy Martin

52  EARLY CLINICAL OUTCOMES AFTER PELVIC INTERSTITIAL BRACHYTHERAPY USING 3D-PRINTED PATIENT-SPECIFIC CUSTOM VAGINAL TEMPLATES IN BRITISH COLUMBIA  
Francois Bachand

53  COMPARING DOSIMETRY OF LOCALLY ADVANCED CERVIX CANCER PATIENTS TREATED WITH 3 VERSUS 4 FRACTIONS OF MRI-GUIDED BRACHYTHERAPY  
Aba Scott

54  RADIOBIOLOGICAL RESPONSE TO BRACHYTHERAPY: CERVICAL SQUAMOUS CELL CARCINOMA VERSUS ADENOCARCINOMA PARAMETERS, QUANTIFIED IN VITRO  
Braden Chow

10:00-10:30  
Refreshment Break

10:30-12:00  
**CARO-ESTRO Symposium - TB I**  
Moderators:

Title:
Speakers:

Objectives: By the end of this session, the participants will be able to:
Xx  
Xx

11:30-12:00  
Discussion Period
12:00-12:15
Refreshment/Stretch Break

12:15-1:15
Plenary Abstracts - TB I
Moderators:

Objectives: By the end of this session, the participants will be able to:
Xx
Xx

55 EVALUATION OF PATIENT REPORTED OUTCOME DIFFERENCES BY RADIOTHERAPY TECHNIQUE FOR BONE METASTASES IN A NON-INCENTIVIZED HEALTH CARE SYSTEM
Robert Olson

56 PHASE 2 TRIAL OF NEOADJUVANT METFORMIN AND TEMOZOLOMIDE FOLLOWED BY HYPOFRACTIONATED ACCELERATED RADIOTHERAPY WITH CONCOMITANT AND ADJUVANT METFORMIN AND TEMOZOLOMIDE IN PATIENTS WITH NEWLY DIAGNOSED GlioBLASTOM
George Shenouda

57 ACCELERATED PARTIAL BREAST IRRADIATION (APBI) USING FIVE DAILY FRACTIONS: A PROSPECTIVE, PHASE II, MULTI-CENTRE TRIAL OF COSMETIC OUTCOMES AND TOXICITY (THE ACCEL TRIAL): FINAL RESULTS
Petra Grendarova

58 EVALUATING THE SHORT-TERM ENVIRONMENTAL AND CLINICAL EFFECTS OF A RADIATION ONCOLOGY DEPARTMENT'S RESPONSE TO THE COVID-19 PANDEMIC (STEER COVID-19)
Philip Wong

1:15-1:30
Closing Remarks - TB I

Poster Abstracts 59-189